Terms: = Uterine cancer AND HER1, YOR227W AND Prognosis
4 results:
1. A pan-HER-targeted approach for recurrent or late-stage cervical cancer therapy: mechanisms, recent advances, and clinical prospects.
Liu Y; An Q; Zhao X
Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4123-4131. PubMed ID: 32373948
[TBL] [Abstract] [Full Text] [Related]
2. The prognostic significance of human epidermal growth factor receptor correlations in squamous cell cervical carcinoma.
Fuchs I; Vorsteher N; Bühler H; Evers K; Sehouli J; Schaller G; Kümmel S
Anticancer Res; 2007; 27(2):959-63. PubMed ID: 17465227
[TBL] [Abstract] [Full Text] [Related]
3. [Molecular diagnostic and targeted therapy--"Barking dogs are going to bite": presentations from the 42nd Annual Meeting of the American Society of Clinical Oncology, Atlanta 2006].
Rody A; Loibl S; Kaufmann M
Zentralbl Gynakol; 2006 Oct; 128(5):233-41. PubMed ID: 17001557
[TBL] [Abstract] [Full Text] [Related]
4. Expression of the epidermal growth factor system in endometrioid endometrial cancer.
Ejskjaer K; Sørensen BS; Poulsen SS; Forman A; Nexø E; Mogensen O
Gynecol Oncol; 2007 Jan; 104(1):158-67. PubMed ID: 16962163
[TBL] [Abstract] [Full Text] [Related]
